Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191801 | 0.88 | MAPT (0.33) | CA1CA2ALDH1A1APEX1MAPT | |
| SCHEMBL17277942 | 0.87 | APEX1 (0.34) | CA1CA2ALDH1A1GAANR1I2 | |
| SCHEMBL26607 | 0.81 | CA1 (0.41) | CA1CA2ALDH1A1GAAAPEX1 | |
| SCHEMBL29349873 | 0.81 | CA1 (0.41) | CA1CA2ALDH1A1GAAAPEX1 | |
| SCHEMBL18828155 | 0.81 | CA1 (0.36) | CA1CA2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL30252476 | 0.81 | CA1 (0.36) | CA1CA2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL31720630 | 0.80 | CA1 (0.40) | CA1CA2ALDH1A1GAAAPEX1 | |
| SCHEMBL19514039 | 0.80 | CA1 (0.40) | CA1CA2ALDH1A1GAAAPEX1 | |
| Potassium SCHEMBL31621706 | 0.80 | CA1 (0.40) | CA1CA2ALDH1A1GAAAPEX1 | |
| Phosphine SCHEMBL7943984 | 0.80 | CA1 (0.40) | CA1CA2ALDH1A1GAAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127444-A1 | BISPHOSPHITES HAVING 2,4-TERT-BUTYLPHENYL UNITS AND USE THEREOF AS LIGANDS IN HYDROFORMYLATION | EVONIK DEGUSSA GMBH (DE) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127444-A1 | BISPHOSPHITES HAVING 2,4-TERT-BUTYLPHENYL UNITS AND USE THEREOF AS LIGANDS IN HYDROFORMYLATION | BPGM, NUDT1, PHPT1 | CA1 1923/4885CA2 689/4885ALDH1A1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.